Yogesh Jeelall
@yogeshjeelall.bsky.social
MD PhD, Haematology Trainee and Adjunct Research Fellow, Medical School, University of Western Australia interested in #Haematology #Genomics #ClonalEvolution #DataScience #Immunology
Reposted by Yogesh Jeelall
The Capstan Therapeutics team is exceptional. This is just the beginning of transforming the delivery of CAR T cell immunotherapies www.science.org/doi/10.1126/...
In vivo CAR T cell generation to treat cancer and autoimmune disease
Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity f...
www.science.org
June 30, 2025 at 12:42 PM
The Capstan Therapeutics team is exceptional. This is just the beginning of transforming the delivery of CAR T cell immunotherapies www.science.org/doi/10.1126/...
Reposted by Yogesh Jeelall
check out our study on outcomes in patients with CBF-AML treated with intensive chemotherapy regimens!
pubmed.ncbi.nlm.nih.gov/39157611/
pubmed.ncbi.nlm.nih.gov/39157611/
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia - PubMed
Core-binding factor acute myeloid leukemia (CBF-AML) is characterized by the presence of inv(16)/t(16;16) or t(8;21) and is classified as a favorable risk by the 2022 European LeukemiaNet (ELN) guidel...
pubmed.ncbi.nlm.nih.gov
March 11, 2025 at 7:53 PM
check out our study on outcomes in patients with CBF-AML treated with intensive chemotherapy regimens!
pubmed.ncbi.nlm.nih.gov/39157611/
pubmed.ncbi.nlm.nih.gov/39157611/